“Why do we take so much blood, particularly from the frail when we need so little! It’s unethical.” - Neil Spooner, Spooner Bioanalytical, CPSA Colloquia, 25 October 2017.
This means that microsampling must evolve – it is the foundation...
We started with blood and skin.
The microbiopsy device is under development and supplied for research purposes only. This device is not for therapeutic or diagnostic use.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research purposes only and not for therapeutic or diagnostic use.
Microsampling enables:
“Why do we take so much blood, particularly from the frail when we need so little! It’s unethical.” - Neil Spooner, Spooner Bioanalytical, CPSA Colloquia, 25 October 2017.
hemaPEN® is a microsampling tool that enables the collection of four volumetrically fixed, accurate and precise, samples from a single source.
hemaPEN exemplifies the advantages of dried blood spot (DBS) micro-sample stability, while addressing the associated limitations of volumetric accuracy, hematocrit effect and sample integrity.
While traditional biopsies collect a chunk of skin several millimetres across, this microbiopsy device takes only a very small skin sample, removing the need for anaesthesia and sutures and leaving only a pinprick-like wound behind.
"It takes only a quarter of a millimetre of skin – or 1,500 cells – for molecular diagnosis, which eliminates the unnecessary excision of suspicious benign lesions and alleviates the fear of excisions that many people have in the diagnostic process." - Professor H Peter Soyer
More information at Minimizing trauma of skin biopsies - Trajan and UniQuest to form partnership for the commercialization and continued development of devices for microsampling human tissue.
The microbiopsy device is under development and supplied for research purposes only. This device is not for therapeutic or diagnostic use.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research purposes only and not for therapeutic or diagnostic use.
hemaPEN has been designed to effectively integrate with laboratory workflows:
Trajan is building a suite of technologies and solutions around hemaPEN as a platform technology that can be applied to any microsampling workflow challenge:
226™ is a trademark of PerkinElmer, Inc or its affiliated entities. 903® is a registered trademark of Eastern Business Forms, Inc.
We are working with ASTech - ARC Training Centre for Portable Analytical Separation Technologies on hemaPEN and sample separation.
We are working with UniQuest, University of Queensland (UQ) to develop and commercialize devices for microsampling human tissue.
More information about UQ Dermatology Research Centre.
We are working with the Future Industries Institute (FII) at University of South Australia (UniSA) on microbiopsy development.
Trajan collaborated with D+I (Design + Industry) in the development of hemaPEN® from initial concepts to prototype device for research and investigational use.
Spooner Bioanalytical Solutions is consulting to Trajan by way of providing expert review, advice and opinion in the area of microsampling.
Weekly, do-it-yourself blood samples are being pushed as the future of preventative medicine by the Melbourne minds behind the hemaPEN. @msanto92 #9News pic.twitter.com/w4tYPleIYJ
— Nine News Melbourne (@9NewsMelb) April 17, 2019
